Cell therapy is a novel process of injecting, grafting, or implanting viable cells to the patients in order to achieve a therapeutic effect.
“Global Cell Therapy Market Outlook, Patent & Clinical Trials Insight 2028" Report Highlights:
- Global Cell Therapy Market Opportunity: > USD 45 Billion By 2028
- Cell Therapy Clinical Trial Insight by Indication, Company and Country
- Insight On More than 1600 Cell Therapies in Clinical Trials
- Clinical & Commercial Insight On 32 Cell Therapies Available in Market
- Dosage & Pricing Insight By Country & Region
- COVID-19 Impact Analysis on Global market & Clinical Trials
- Price & Product Insight By Region/Country
Download Report:
Cell therapy is a novel process of injecting, grafting, or implanting viable cells to the patients in order to achieve a therapeutic effect. The novel therapy is primarily used for the management of cancer, infectious diseases, urinary problems, and autoimmune disorders. Additionally, it is helpful in repairing spinal cord injuries, rebuilding damaged cartilage in joints, improving a weakened immune system, and improving patients with neurological disorders. Till date, a cocktail of cell therapy products have been approved by regulatory bodies which have shown robust response in the market. For instance in 2021, US FDA approved Abecma which is the first cell based therapy for the management of multiple myeloma.
The encouraging response of approved cell therapy products in the market has propelled the further research and development activities in this segment. Recently, researchers have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that has shown success in pre-clinical studies. The new B-cell activating factor (BAFF) CAR T product developed by the researchers binds specifically to three receptors instead of one – BAFF-R, BCMA and TACI, providing more therapeutic options. Several ongoing clinical trials are also evaluating the role of cell therapy in non-oncological conditions, which have demonstrated positive results. Recently Tevogen Bio announced positive safety data from second cohort in ongoing proof of concept trial of TVGN-489, its investigational T cell therapy in COVID-19 patients.
Furthermore, the regulatory bodies are also encouraging the development of novel cell therapy products by granting several designations including orphan, PRIME, Breakthrough Therapy, Priority review, and others to expedite the drug development and approval process. For example, FDA granted egenerative medicine advanced therapy (RMAT) designation to FT516, a natural killer cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma. In addition, FDA granted fast track designation to CYNK-001 for the treatment of adults with relapsed or refractory acute myeloid leukemia. CYNK-001 (Celularity) is a nongenetically modified allogeneic natural killer (NK) cell therapy.
The novel cell therapy is emerging as an exciting field which has gained considerable attention from the pharmaceutical companies. The companies are developing new cell therapy products for novel therapeutic conditions by entering into collaboration or partnerships. For example collaboration between ViaCyte and CRISPR Therapeutics, a new clinical trial is investigating a cell therapy that may eventually help millions with type 1 diabetes. Further in 2022, Morphocell Technologies announced the development of an innovative, scalable method for generating cells that may enable future cell therapies for liver diseases and improve the way these conditions are studied in the lab and how future medications for other illnesses are developed.
As per our analysis, the global cell therapy market is expected to surpass US$ 40 Billion by 2028. Change in lifestyle and dietary habits leads to various chronic diseases. Hence, surge in number of patients with chronic diseases is anticipated to drive the global cell therapy market. The increasing number of product approvals and a growing number of clinical trials for cell therapy products gives a new shape to the cell therapy market. In addition, the advancements in cell therapy as well as the launch of innovative technologies have paved the way for a new era in biological therapeutics, which will further boost the growth of market during the forecast period.
This report provide in-depth analysis of the global cell therapy market and provide information on approved cell therapy products along with their price, dosage, ongoing clinical trials, and patent insights. A comprehensive analysis on the ongoing clinical trials as well as major key drugs in research and development is also included in the report. This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366